CN108430551A - 尼古丁颗粒封壳 - Google Patents
尼古丁颗粒封壳 Download PDFInfo
- Publication number
- CN108430551A CN108430551A CN201680071326.0A CN201680071326A CN108430551A CN 108430551 A CN108430551 A CN 108430551A CN 201680071326 A CN201680071326 A CN 201680071326A CN 108430551 A CN108430551 A CN 108430551A
- Authority
- CN
- China
- Prior art keywords
- capsule
- nicotine
- particle
- capsule according
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 106
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title claims abstract description 102
- 239000002245 particle Substances 0.000 title claims abstract description 102
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title claims abstract description 97
- 229960002715 nicotine Drugs 0.000 title claims abstract description 96
- 239000000843 powder Substances 0.000 claims description 41
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 4
- FFYVQVZXWDGRAY-UHFFFAOYSA-N 3-(1-methylpyrrolidin-2-yl)pyridine;hydrate Chemical compound O.CN1CCCC1C1=CC=CN=C1 FFYVQVZXWDGRAY-UHFFFAOYSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims description 2
- 235000007164 Oryza sativa Nutrition 0.000 claims description 2
- 235000009566 rice Nutrition 0.000 claims description 2
- 239000000686 essence Substances 0.000 description 26
- 239000002304 perfume Substances 0.000 description 24
- 239000003205 fragrance Substances 0.000 description 21
- 239000000463 material Substances 0.000 description 16
- 210000004072 lung Anatomy 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 230000000391 smoking effect Effects 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019580 granularity Nutrition 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 6
- 238000005054 agglomeration Methods 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000005253 cladding Methods 0.000 description 4
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 4
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 4
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 244000246386 Mentha pulegium Species 0.000 description 3
- 235000016257 Mentha pulegium Nutrition 0.000 description 3
- 235000004357 Mentha x piperita Nutrition 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 235000019504 cigarettes Nutrition 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000011194 food seasoning agent Nutrition 0.000 description 3
- 235000001050 hortel pimenta Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 2
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 2
- JZBCTZLGKSYRSF-UHFFFAOYSA-N 2-Ethyl-3,5-dimethylpyrazine Chemical compound CCC1=NC=C(C)N=C1C JZBCTZLGKSYRSF-UHFFFAOYSA-N 0.000 description 2
- BWLBGMIXKSTLSX-UHFFFAOYSA-N 2-hydroxyisobutyric acid Chemical compound CC(C)(O)C(O)=O BWLBGMIXKSTLSX-UHFFFAOYSA-N 0.000 description 2
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- 241000522254 Cassia Species 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 244000024873 Mentha crispa Species 0.000 description 2
- 235000014749 Mentha crispa Nutrition 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- -1 gaultherolin Substances 0.000 description 2
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 2
- CATSNJVOTSVZJV-UHFFFAOYSA-N heptan-2-one Chemical compound CCCCCC(C)=O CATSNJVOTSVZJV-UHFFFAOYSA-N 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229930007744 linalool Natural products 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 229940069688 nicotine bitartrate Drugs 0.000 description 2
- LDMPZNTVIGIREC-ZGPNLCEMSA-N nicotine bitartrate Chemical compound O.O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.CN1CCC[C@H]1C1=CC=CN=C1 LDMPZNTVIGIREC-ZGPNLCEMSA-N 0.000 description 2
- DTUQWGWMVIHBKE-UHFFFAOYSA-N phenylacetaldehyde Chemical compound O=CCC1=CC=CC=C1 DTUQWGWMVIHBKE-UHFFFAOYSA-N 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 2
- WTOYNNBCKUYIKC-JMSVASOKSA-N (+)-nootkatone Chemical compound C1C[C@@H](C(C)=C)C[C@@]2(C)[C@H](C)CC(=O)C=C21 WTOYNNBCKUYIKC-JMSVASOKSA-N 0.000 description 1
- GKTOAHZEMRRUKF-HVDRVSQOSA-N (2s)-2-aminopentanedioic acid;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound OC(=O)[C@@H](N)CCC(O)=O.CN1CCCC1C1=CC=CN=C1 GKTOAHZEMRRUKF-HVDRVSQOSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- 239000001363 2-ethyl-3,5-dimethylpyrazine Substances 0.000 description 1
- AIBWPBUAKCMKNS-PPHPATTJSA-N 2-hydroxybenzoic acid;3-[(2s)-1-methylpyrrolidin-2-yl]pyridine Chemical compound OC(=O)C1=CC=CC=C1O.CN1CCC[C@H]1C1=CC=CN=C1 AIBWPBUAKCMKNS-PPHPATTJSA-N 0.000 description 1
- VWTHFJXLFGINSW-PPHPATTJSA-N 2-hydroxypropanoic acid;3-[(2s)-1-methylpyrrolidin-2-yl]pyridine Chemical compound CC(O)C(O)=O.CN1CCC[C@H]1C1=CC=CN=C1 VWTHFJXLFGINSW-PPHPATTJSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- IRJNJBIOUYJBHG-UHFFFAOYSA-N 3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound CN1CCCC1C1=CC=CN=C1.CN1CCCC1C1=CC=CN=C1 IRJNJBIOUYJBHG-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- HDJBTCAJIMNXEW-PPHPATTJSA-N 3-[(2s)-1-methylpyrrolidin-2-yl]pyridine;hydrochloride Chemical compound Cl.CN1CCC[C@H]1C1=CC=CN=C1 HDJBTCAJIMNXEW-PPHPATTJSA-N 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 241001166194 Geranium wilfordii Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- YKVWPZJHENXDAJ-VOTSOKGWSA-N Megastigmatrienone Chemical compound CC1=CC(=O)CC(C)(C)C1\C=C\C=C YKVWPZJHENXDAJ-VOTSOKGWSA-N 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000002386 air freshener Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- POIARNZEYGURDG-FNORWQNLSA-N beta-damascenone Chemical compound C\C=C\C(=O)C1=C(C)C=CCC1(C)C POIARNZEYGURDG-FNORWQNLSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- RHDGNLCLDBVESU-UHFFFAOYSA-N but-3-en-4-olide Chemical compound O=C1CC=CO1 RHDGNLCLDBVESU-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000001926 citrus aurantium l. subsp. bergamia wright et arn. oil Substances 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000011246 composite particle Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- WTOYNNBCKUYIKC-UHFFFAOYSA-N dl-nootkatone Natural products C1CC(C(C)=C)CC2(C)C(C)CC(=O)C=C21 WTOYNNBCKUYIKC-UHFFFAOYSA-N 0.000 description 1
- 239000003571 electronic cigarette Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000010648 geranium oil Substances 0.000 description 1
- 235000019717 geranium oil Nutrition 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000010649 ginger oil Substances 0.000 description 1
- 229960001867 guaiacol Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZYDGQQTXLBNSGJ-UHFFFAOYSA-N oxonan-2-one Chemical compound O=C1CCCCCCCO1 ZYDGQQTXLBNSGJ-UHFFFAOYSA-N 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N pentanal Chemical compound CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 229940100595 phenylacetaldehyde Drugs 0.000 description 1
- ULSIYEODSMZIPX-UHFFFAOYSA-N phenylethanolamine Chemical compound NCC(O)C1=CC=CC=C1 ULSIYEODSMZIPX-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- PQDRXUSSKFWCFA-CFNZNRNTSA-N solanone Chemical compound CC(=O)CC[C@@H](C(C)C)\C=C\C(C)=C PQDRXUSSKFWCFA-CFNZNRNTSA-N 0.000 description 1
- PQDRXUSSKFWCFA-UHFFFAOYSA-N solanone Natural products CC(=O)CCC(C(C)C)C=CC(C)=C PQDRXUSSKFWCFA-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 229930007850 β-damascenone Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/24—Treatment of tobacco products or tobacco substitutes by extraction; Tobacco extracts
- A24B15/241—Extraction of specific substances
- A24B15/243—Nicotine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/186—Treatment of tobacco products or tobacco substitutes by coating with a coating composition, encapsulation of tobacco particles
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F15/00—Receptacles or boxes specially adapted for cigars, cigarettes, simulated smoking devices or cigarettes therefor
- A24F15/01—Receptacles or boxes specially adapted for cigars, cigarettes, simulated smoking devices or cigarettes therefor specially adapted for simulated smoking devices or cigarettes therefor
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F42/00—Simulated smoking devices other than electrically operated; Component parts thereof; Manufacture or testing thereof
- A24F42/20—Devices without heating means
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F42/00—Simulated smoking devices other than electrically operated; Component parts thereof; Manufacture or testing thereof
- A24F42/60—Constructional details
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0033—Details of the piercing or cutting means
- A61M15/0035—Piercing means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
一种含有包含尼古丁的颗粒的封壳,其中单个开孔延伸穿过所述封壳。
Description
技术领域
本公开涉及一种尼古丁颗粒封壳单个开孔。所述尼古丁颗粒封壳可以是适合用在干粉吸入器中的消耗品。
背景技术
干粉吸入器未必总是完全适合于以常规吸烟方式吸入速率或气流速率内的吸入速率或气流速率将干粉提供到肺。干粉吸入器通常力求在单次呼吸中提供整剂干粉。
期望的是提供一种尼古丁颗粒制品,其可与干粉吸入器组合以在常规吸烟方式吸入速率或气流速率内的吸入速率或气流速率下将包括尼古丁的颗粒提供到肺。还期望提供一种尼古丁颗粒制品,其可在至少5次抽吸或至少10次抽吸里释放包括尼古丁的颗粒。
发明内容
本公开涉及一种含有包括尼古丁的颗粒的封壳,其中单个开孔延伸穿过所述封壳。所述单个开孔大小可设定成在结合干粉吸入器利用时随着每次抽吸或吸入而提供小部分量的包括尼古丁的颗粒。
所述封壳可适合用在干粉吸入器中。所述封壳可以是适合用在干粉吸入器中的制品的部分。所述封壳可以是多次使用的干粉吸入器的模块组件。所述封壳可在多次使用干粉吸入器内轻松更换。一旦耗尽,所述封壳或制品就可从多次使用干粉吸入器中移除且舍弃。
有利的是,所述单个开孔大小可设定成在消费者的五次或更多次、或十次或更多次、或15次或更多次“抽吸”中提供来自所述封壳的部分或一小部分尼古丁颗粒的均匀夹带。
本文所描述的封壳可在与干粉吸入器组合时以常规吸烟方式吸入速率或气流速率内的吸入速率或气流速率将干粉(包括尼古丁颗粒)提供到肺。消费者可进行多次“抽吸”,其中每次“抽吸”会递送含于封壳腔内的封壳内所含的一小部分量干粉。这可模仿常规吸烟的状态。
术语“尼古丁”是指尼古丁和尼古丁衍生物,如游离尼古丁、尼古丁盐等。
术语“香料”或“香精”是指改变和旨在改变尼古丁在其消耗或吸入期间的味道或芳香特性的感官化合物、组合物或材料。优选的是,术语“香料”或“香精”是指在以下各者中公开的化合物:香料和萃取物制造者协会(FEMA)香料成分库(Flavor&ExtractManufacturers Association(FEMA)Flavor Ingredient Library),且尤其是例如GRAS调味物质(GRAS Flavoring Substances)出版物3到27,参见Hall,R.L.和Oser,B.L.,《食品科技》(Food Technology),1965年2月第151-197页,以及GRAS调味物质27,S.M.Cohen等人,《食品科技》,2015年8月第40-59页,以及中间的GRAS调味物质出版物4到26。出于本公开的目的,不将尼古丁视为香料或香精。
所述封壳可与刺破元件或刺破装置组合以在所述封壳中形成所述单个开孔。所述刺破元件或刺破装置可与吸入器制品的部分分开或不分开。多个所述封壳或包括所述封壳的制品可与干粉吸入器组合以形成成套装置。
所述封壳包含一个且仅一个延伸穿过所述封壳的开孔。所述封壳不包括多于一个的延伸穿过所述封壳的开孔。空气可从同一单个开孔流入和流出。
所述封壳含有包括尼古丁的颗粒。所述封壳还可含有并不包括尼古丁的颗粒。包括尼古丁的颗粒和不包括尼古丁的颗粒可构成干粉。
包括尼古丁的颗粒可具有约5微米或更低、或在约0.5微米到约4微米的范围内、或在约1微米到约3微米的范围内或在约1.5微米到约2.5微米的范围内的质量中值空气动力学直径。优选的是,利用阶式撞击取样器测量质量中值空气动力学直径。
干粉可具有约60微米或更低、或在约1微米到约40微米的范围内、或在约1.5微米到约25微米的范围内的平均直径。平均直径是指单位质量的平均直径,且优选通过激光衍射、激光漫射或电子显微镜测量。
所述单个开孔可具有约0.1mm到4mm、或0.2mm到2mm、或约0.5mm到约1.5mm、或约0.6mm到约1mm、或约0.7mm到约0.9mm或约0.8mm的直径。所述单个开孔可具有约0.1mm2到约2mm2、或约0.2mm2到约1mm2或约0.4到约0.6mm2的开口表面积。
所述单个开孔的直径对包括尼古丁的颗粒的质量中值空气动力学直径的比率可以是约50到约3200,或约100到约1600,或约200到约800,或约300到约600。
所述单个开孔的直径对干粉的平均直径的比率可以是约5到约320,或约10到约160,或约20到约80,或约30到约60。
所述单个开孔可与所述封壳的纵向轴线相伴随。当封壳放置于干粉吸入器中且被刺破时,穿过干粉吸入器的气流可使封壳围绕封壳的纵向轴线旋转。
所述封壳可限定内部容积,被称作封壳的内部容积。封壳的内部容积可以是0.02ml到约3ml、或约0.1ml到约0.9ml、或约0.2ml到约0.45ml、或约0.25ml到约0.3ml。所述单个开孔的开口表面积可以是每ml封壳内部容积约0.7mm2到约7mm2或每ml封壳内部容积约1mm2到约2mm2。
所述封壳可含有约10mg到约200mg或约20mg到约100mg或40mg到70mg的干粉。所述封壳可含有约10mg到约200mg或约20mg到约100mg或40mg到70mg的包括尼古丁的颗粒。
所述制品或封壳可安置在干粉吸入器的封壳腔中。所述封壳腔可限定配置成容纳所述封壳(其可具有长圆形形状)的圆柱形空间。沿着所述封壳腔的长度,所述封壳腔可具有基本上均匀或均匀的直径。沿着所述封壳腔的长度,所述封壳腔可具有基本上圆柱形或圆柱形的横截面。所述封壳腔相对于封壳的配置可允许封壳在封壳腔内稳定旋转。在吸入期间,封壳的纵向轴线可围绕吸入器主体的纵向轴线稳定旋转。
稳定旋转是指吸入器主体的纵向轴线基本上平行于封壳的旋转轴线。稳定旋转可指旋转的封壳不存在行进。优选的是,吸入器主体的纵向轴线可大体上与封壳的旋转轴线共同延伸。封壳的稳定旋转可在消费者的五次或更多次、或十次或更多次、或15次或更多次“抽吸”中提供来自封壳的尼古丁颗粒的部分的均匀夹带。
所述封壳腔可具有与纵向轴线正交的腔内径,且所述封壳具有封壳外径。所述封壳外径可在从腔内径的约80%到约99%的范围内,或封壳外径可在从腔内径的约85%到约95%的范围内,或封壳外径可约为腔内径的90%。所述封壳外径可在约5.4mm到约6.4mm的范围内且腔内径可在约6mm到约7mm的范围内,或所述封壳外径可在约5.7mm到约6.1mm的范围内且腔内径可在约6.4mm到约6.8mm的范围内,或所述封壳外径可为约5.85mm且腔内径可为约6.6mm。
所述封壳腔在上游侧可由端盖定界,且在下游侧由多孔支撑元件定界。所述端盖和多孔支撑元件协作以将封壳纵向容纳于封壳腔内。所述多孔支撑元件可填满细长吸入器主体的内径。所述多孔支撑元件可允许气流通过所述多孔支撑元件来沿着细长吸入器主体的横截面呈现均匀气流。所述多孔支撑元件可充当散流器以减小湍流效应或边缘效应,且确保或维持穿过封壳腔的所要气流模式。
所述多孔支撑元件可具有沿着纵向轴线延伸约20mm到约40mm、或约22mm到约35mm、或约25mm到约30mm、或约27mm的距离的长度。所述多孔支撑元件可具有足以形成与吸入器主体的内径的摩擦配合的外径。所述多孔支撑元件可具有范围约5mm到约10mm、或约6mm到约9mm、或约6.5mm到约8.5mm、或约7.5mm的外径。
所述多孔支撑元件可限定过滤器元件。所述过滤器元件可由纤维网络形成。所述纤维网络可以是非编织纤维元件。所述多孔支撑元件可以是过滤材料条。形成所述多孔支撑元件的纤维可从聚乳酸获得。形成所述多孔支撑元件的纤维可以是醋酸纤维素。所述过滤器元件可以是醋酸纤维素条或聚乳酸条。多孔元件可包括塑料网格。所述塑料网格可具有约1mm2到约4mm2或约2mm2的孔洞。
所述封壳在消耗之前可密封在吸入器制品内。所述吸入器制品可容纳于密封或气密容器或袋内。吸入器制品可包含一个或多个可剥离密封层以覆盖吸入器制品的一个或多个空气入口通道或空气出口或衔嘴。
所述封壳可在空气流动通过吸入器制品时围绕其纵向或中心轴线旋转。所述封壳可由气密材料形成,可通过可与吸入器分开或组合的刺破元件来刺破或刺穿所述气密材料以形成单个开孔。所述封壳可由金属或聚合材料形成,所述金属或聚合材料用于保持封壳不受污染但可在消耗封壳内的尼古丁颗粒之前通过刺破元件刺破或刺穿。所述封壳可由聚合材料形成。所述聚合材料可以是羟丙基甲基纤维素(HPMC)。所述封壳可以是1号到4号或3号封壳。
金属或刚性针等单独的刺破元件可形成穿过收纳于封壳腔中的封壳的单个开孔。所述刺破元件可穿过密封端盖上的刺破通道的可重复密封的元件。
所述封壳含有包括尼古丁的尼古丁颗粒(也称为“尼古丁粉末”或“尼古丁颗粒”),且任选地含有包括香精的颗粒(也称为“香精颗粒”)。所述封壳可含有预定量的尼古丁颗粒和任选的香精颗粒。所述封壳可含有足够尼古丁颗粒以提供至少5次吸入或“抽吸”,或至少约10次吸入或“抽吸”,或至少约15次吸入或“抽吸”。所述封壳可含有足够尼古丁颗粒以提供约5次到约50次吸入或“抽吸”、或约10次到约30次吸入或“抽吸”。每次吸入或“抽吸”可将约0.1mg到约3mg的尼古丁颗粒递送到用户的肺,或将约0.2mg到约2mg的尼古丁颗粒递送到用户的肺,或将约1mg的尼古丁颗粒递送到用户的肺。
基于所用的具体调配,所述尼古丁颗粒可具有任何适用的尼古丁浓度。所述尼古丁颗粒可具有至少约1%wt的尼古丁直到约30%wt的尼古丁,或约2%wt到约25%wt的尼古丁,或约3%wt到约20%wt的尼古丁,或约4%wt到约15%wt的尼古丁,或约5%wt到约13%wt的尼古丁。优选的是,每次“抽吸”可将约50到约150微克的尼古丁递送到用户的肺。
所述封壳可保持或含有至少约5mg的尼古丁颗粒或至少约10mg的尼古丁颗粒。所述封壳可保持或含有低于约900mg的尼古丁颗粒,或小于约300mg的尼古丁颗粒,或小于150mg的尼古丁颗粒。所述封壳可保持或含有约5mg到约300mg的尼古丁颗粒或约10mg到约200mg的尼古丁颗粒。
当香精颗粒与尼古丁颗粒掺混或组合于封壳内时,香精颗粒的存在量可将所要香味提供到递送到用户的每次吸入或“抽吸”。
尼古丁颗粒3]可具有适用于优先吸入递送到用户的肺中的任何粒度分布。所述封壳可包含并非尼古丁颗粒的颗粒。所述尼古丁颗粒和其它颗粒可形成粉末系统。
所述封壳可保持或含有至少约5mg的干粉(也称作粉末系统)或至少约10mg的干粉。所述封壳可保持或含有低于约900mg的干粉,或小于约300mg的干粉,或小于约150mg的干粉。所述封壳可保持或含有约5mg到约300mg的干粉或约10mg到约200mg的干粉。
所述干粉或粉末系统可使至少约40重量%或至少约60重量%或至少约80重量%的所述粉末系统包含在具有约10微米或更低、或5微米或更低、或范围约1微米到约3微米的粒度的尼古丁颗粒中。
粉末系统或尼古丁颗粒中的尼古丁可以是医药学上可接受的游离尼古丁或尼古丁盐或尼古丁盐水合物。适用的尼古丁盐或尼古丁盐水合物包含例如尼古丁丙酮酸盐、尼古丁柠檬酸盐、尼古丁天冬氨酸盐、尼古丁乳酸盐、尼古丁酒石酸氢盐、尼古丁水杨酸盐、尼古丁延胡索酸盐、尼古丁单丙酮酸盐、尼古丁谷氨酸盐或尼古丁盐酸盐。与尼古丁组合形成盐或水合盐的化合物可基于其预期药理学作用来进行选择。
优选的是,所述尼古丁颗粒包含氨基酸。优选的是,氨基酸可以是亮氨酸,如L-亮氨酸。结合包括尼古丁的颗粒提供L-亮氨酸等氨基酸可减小包括尼古丁的颗粒的粘着力,且可减小尼古丁颗粒之间的引力且因此减小尼古丁颗粒的附聚。类似地,还可减小与包括香精的颗粒的粘着力,由此还减少尼古丁颗粒与香精颗粒的附聚。因此,本文所述的粉末系统可以是自由流动材料且每种粉末组分都具有稳定的相对粒度,甚至在尼古丁尼古丁与香精颗粒组合时仍如此。
优选的是,所述尼古丁可以是表面改性的尼古丁盐,其中尼古丁盐颗粒包括包覆或复合颗粒。优选的包覆或复合材料可以是L-亮氨酸。一种尤其适用的尼古丁颗粒可以是结合L-亮氨酸的尼古丁酒石酸氢盐。
所述粉末系统可包含香精颗粒。香精颗粒可具有适用于选择性地吸入递送到用户口中或颊腔中的任何粒度分布。
粉末系统可使粉末系统的香精的至少约40重量%、或至少约60重量%、或至少约80重量%包含在具有约20微米或更大粒度的颗粒中。粉末系统可使粉末系统的香精的至少约40重量%、或至少约60重量%、或至少约80重量%包含在具有约50微米或更大粒度的颗粒中。粉末系统可以使粉末系统的香精的至少约40重量%、或至少约60重量%、或至少约80重量%包含在粒度范围从约50微米到约150微米的颗粒中。包括香精的颗粒可具有约20微米或更大、或约50微米或更大、或范围在约50到约200微米或从约50到约150微米的质量中值空气动力学直径。优选的是,利用阶式撞击取样器测量质量中值空气动力学直径。
香料或香精可作为固体香精(在约22摄氏度的室温和一个大气压下)提供,且可包含香精调配物、含香精材料和香精前体。香料可包含一种或多种天然香料、一种或多种合成香料、或天然香料与合成香料的组合。如本文所述的香料是选择且用以改变或旨在改变尼古丁组分在其消耗或吸入期间的味道或芳香特征的感官化合物、组合物或材料。
香料或香精是指天然或合成来源的多种香味材料。其包含单一化合物和混合物。所述香精或香料具有可在消耗期间增强尼古丁组分体验的香味性质。可选择香精以提供与抽吸可燃吸烟制品所产生的体验类似的体验。举例来说,香精或香料可增强满口感和复杂感。复杂感一般是指香味更丰富而不主导单一感官属性的总体平衡状态。满口感被描述为消费者口中和喉中丰富度和量的感知。
合适的香精包含但不限于任何天然或合成香精,例如烟草、烟、薄荷醇、薄荷(例如胡椒薄荷和绿薄荷)、巧克力、甘草、柑橘类植物和其它果味香精、丙位辛内酯、香草醛、乙基香草醛、空气清新剂香精、肉桂等调味香精、水杨酸甲酯、芳樟醇、香柠檬油、老鹳草油、柠檬油和姜油等。
其它合适的香精可包含选自由酸、醇、酯、醛、酮、吡嗪、其组合或混合物等组成的群组的香味化合物。合适的香味化合物可例如选自由苯乙酸、茄酮、巨豆三烯酮、2-庚酮、苯甲醇、顺式-3-己烯醋酸酯、戊酸、戊醛、酯、萜烯、倍半萜烯、圆柚酮、麦芽醇、大马酮、吡嗪、内酯、茴香脑、异戊酸、其组合等组成的群组。
香精的其它具体实例可见于当前文献中,并且是调味、即赋予产品气味或味道领域的技术人员众所周知的。
所述香料可以是高效能香料,且可在将会产生低于吸入气流的200百万分率的量下使用和察觉。此类香料的实例是关键烟草芳香化合物,如β-大马酮、2-乙基-3,5-二甲基吡嗪、苯乙醛、愈创木酚和呋喃酮。其它香料可能仅在较高浓度水平下被人感觉到。这些香料,在本文中被称为低效能香料,通常以产生比释放到吸入空气中的香料量高数个数量级的量来使用。合适的低效能香料包含但不限于天然或合成薄荷醇、胡椒薄荷、绿薄荷、咖啡、茶、调味料(如肉桂、丁香和姜)、可可、香草、果味香精、巧克力、桉属植物、老鹳草、丁子香酚和芳樟醇。
包括香精的颗粒可包含用于减小粘着力或表面能以及所引起的附聚的化合物。香精颗粒可利用减小粘着力的化合物进行表面改性以形成包覆的香精颗粒。一种优选的减小粘着力的化合物可以是硬脂酸镁。结合香精颗粒提供硬脂酸镁等减小粘着力的化合物,尤其是包覆香精颗粒,可减小包括香精的颗粒的粘着力且可减小香精颗粒之间的引力,且因此减小香精颗粒的附聚。因此,也可减少香精颗粒与尼古丁颗粒的附聚。因此,即使在尼古丁颗粒与香精颗粒组合时,本文所描述的粉末系统也可拥有包括尼古丁的颗粒与包括香精的颗粒的稳定的相对粒度。优选的是,所述粉末系统可自由流动。
由于活性颗粒可能太小而不受穿过吸入器的单纯气流影响,因此用于干粉吸入的常规调配物通常含有用以增大活性颗粒的流体化的载体颗粒。所述粉末系统可包括载体颗粒。这些载体颗粒可以是可具有大于约50微米粒度的糖,例如乳糖或甘露醇。载体颗粒可用以通过充当调配物中的稀释剂或疏松剂来提高剂量的均一性。
结合本文所描述的尼古丁粉末递送系统使用的粉末系统可不含载体或基本上不含乳糖或甘露醇等糖。不含载体或基本上不含乳糖或甘露醇等糖可允许以类似于典型吸烟方式吸入速率或气流速率的吸入速率或气流速率将尼古丁吸入且递送到用户肺中。
如上文所描述,包括尼古丁的颗粒和包括香精的颗粒可各自具有减小的粘着力,从而产生稳定的颗粒调配,其中每个组分的粒度在组合时基本上不改变。
尼古丁颗粒和香精颗粒可以任何适用的相对量组合,使得香精颗粒在与尼古丁颗粒一起消耗时被用户察觉到。优选的是,尼古丁颗粒和香精颗粒形成粉末系统总重量的至少约90%wt或至少约95%wt或至少约99%wt或100%wt。
吸入器主体内的单开孔封壳的旋转可使尼古丁颗粒或粉末系统气溶胶化,且可辅助维持自由流动粉末。因此,所述吸入器制品可无需常规吸入器通常利用的较高吸入速率来将上文所描述的尼古丁颗粒递送深入肺中。
所述吸入器制品可使用低于约5L/min、或低于约3L/min、或低于约2L/min、或约1.6L/min的流率。优选的是,所述流率范围可在约1L/min到约3L/min、或约1.5L/min到约2.5L/min。优选的是,所述吸入速率或流率可类似于加拿大卫生部(Health Canada)吸烟范围的速率,即,约1.6L/min。
含有具有仅单个开孔的尼古丁封壳的吸入器可由消费者以类似抽吸常规香烟或抽吸电子香烟的方式使用。此类抽烟或抽蒸汽烟的特征可在于两个步骤:在第一步骤期间,将含有消费者所要的足量尼古丁的小量抽吸到口腔中;接着在第二步骤期间,通过新鲜空气进一步稀释含有包括所要量的尼古丁的气溶胶的所述小量并将其更深地吸入肺中。两个步骤都由消费者控制。在第一吸入步骤期间,消费者可确定待吸入的尼古丁量。在第二步骤期间,消费者可确定用于稀释第一量以更深吸入肺中的量,从而使递送到呼吸道上皮表面的活性剂的浓度最大化。这种吸烟机制有时被称作“抽吸-吸气-呼出”。
除非另外指定,否则本文中所使用的所有科学和技术术语均具有所属领域中常用的含义。本文中所提供的定义是为了便于理解本文中频繁使用的某些术语。
术语“上游”和“下游”是指相对于吸入气流在其被抽吸从远端部分穿过吸入器主体到衔嘴部分时的方向所描述的吸入器的元件的相对位置。
如本文中所使用,除非内容另外明确规定,否则单数形式“一”和“所述”涵盖具有复数指代物的实施例。
如本文所使用,除非内容另外明确规定,否则“或”一般以其包含“和/或”的意义来使用。术语“和/或”意指所列要素中的一个或全部或者所列要素中的任何两个或更多个的组合。
如本文所使用,“具有”、“包含”、“包括”等以其开放意义使用,且一般意指“包含但不限于”。应理解,“主要由…组成”、“由…构成”等归入“包括”等中。
词语“优选的”和“优选的是”是指本发明的在某些情况下可提供某些益处的实施例。然而,在相同或其它情形下,也可优选其它实施例。此外,一个或多个优选实施例的叙述并不暗示其它实施例不适用,且不意图从本公开,包括权利要求书,的范围内排除其它实施例。
附图说明
图1是说明性吸入器制品的透视图。
图2是图1的说明性吸入器制品的沿着纵向轴线的横断面示意图。
图3是具有单个开孔的尼古丁消耗品封壳的示意图端视图。
示意图未必按比例绘制,且出于说明性而非限制性目的而呈现。附图描绘本公开中所描述的一个或多个方面。然而,应理解,附图中未描绘的其它方面处于本公开的范围和精神内。
具体实施方式
图1和图2示出示范性吸入器制品100。图2是图1的说明性吸入器制品的沿着纵向轴线的横断面示意图。吸入器制品100包含沿着纵向轴线LA从衔嘴端112延伸到远端114的主体110和在主体110内限定的封壳腔116。衔嘴空气通道111从封壳腔116延伸到衔嘴端112。端盖120安置在远端112内且延伸到封壳腔116。端盖120从端盖远端124延伸到端盖内端122。端盖120包含从端盖远端124延伸到端盖内端122的空气通道113。空气通道113与纵向轴线LA非平行。
端盖内端122和多孔支撑元件140界定封壳腔116。封壳130安置在腔116内。封壳130含有包括尼古丁的颗粒。端盖120和多孔支撑元件140协作以将封壳130纵向容纳于封壳腔116内。衔嘴端112被示出为具有凹入端,其中主体110在衔嘴端112处界定开放空间。或者,多孔支撑元件140可延伸到衔嘴端112以填充整个衔嘴端112。
图3是具有仅单个开孔220的尼古丁封壳130的示意图端视图。单个开孔220可在封壳主体210的端部部分212处延伸穿过封壳主体210。单个开孔220可与封壳130的纵向轴线相伴随且与吸入器主体110的纵向轴线LA相伴随。
消费者可利用单独的刺破元件(未示出)沿着纵向轴线LA刺破尼古丁封壳130且在端盖120中形成穿过图1中所示的刺破通道的单个开孔220。所述刺破元件可从单个开孔220撤回。消费者可接着将尼古丁封壳130用在吸入器装置100中。
Claims (13)
1.一种含有包括尼古丁的颗粒的封壳,其中单个开孔延伸穿过所述封壳。
2.根据权利要求1所述的封壳,其中所述包括尼古丁的颗粒具有约0.5微米到约4微米的质量中值空气动力学直径。
3.根据前述权利要求中任一项所述的封壳,其中所述单个开孔具有约0.5mm到约1.5mm的直径。
4.根据前述权利要求中任一项所述的封壳,其中所述包括尼古丁的颗粒具有质量中值空气动力学直径且所述单个开孔具有直径,且其中所述单个开孔的所述直径对所述包括尼古丁的颗粒的所述质量中值空气动力学直径的比率是约200到约800。
5.根据前述权利要求中任一项所述的封壳,其中所述尼古丁包括尼古丁盐或尼古丁盐水合物。
6.根据前述权利要求中任一项所述的封壳,其中所述包括尼古丁的颗粒包括氨基酸,例如亮氨酸或L-亮氨酸。
7.根据前述权利要求中任一项所述的封壳,其中所述封壳含有包括香精且具有约20微米或更大或范围从约50微米到约150微米的平均直径的颗粒。
8.根据前述权利要求中任一项所述的封壳,其中所述单个开孔具有约0.2mm2到约1mm2的开口表面积。
9.根据前述权利要求中任一项所述的封壳,其中所述封壳的内部容积是约0.2ml到约0.45ml。
10.根据前述权利要求中任一项所述的封壳,其中所述单个开孔的开口表面积的范围在每ml所述封壳内部容积约0.7mm2到约7mm2。
11.根据前述权利要求中任一项所述的封壳,其中所述封壳含有约10mg到约200mg的干粉。
12.根据前述权利要求中任一项所述的封壳,其中所述单个开孔与所述封壳的纵向轴线相伴随。
13.一种干粉吸入器,其包括根据前述权利要求中任一项所述的封壳。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15202712 | 2015-12-24 | ||
EP15202712.4 | 2015-12-24 | ||
EP16201580 | 2016-11-30 | ||
EP16201580.4 | 2016-11-30 | ||
PCT/IB2016/057792 WO2017109678A1 (en) | 2015-12-24 | 2016-12-19 | Nicotine particle capsule |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108430551A true CN108430551A (zh) | 2018-08-21 |
Family
ID=57822002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680071326.0A Pending CN108430551A (zh) | 2015-12-24 | 2016-12-19 | 尼古丁颗粒封壳 |
Country Status (18)
Country | Link |
---|---|
US (1) | US10960152B2 (zh) |
EP (1) | EP3393565B1 (zh) |
JP (1) | JP7242300B2 (zh) |
KR (1) | KR20180096611A (zh) |
CN (1) | CN108430551A (zh) |
AU (1) | AU2016376033A1 (zh) |
BR (1) | BR112018010830B1 (zh) |
CA (1) | CA3008996A1 (zh) |
ES (1) | ES2948157T3 (zh) |
IL (1) | IL259910A (zh) |
MX (1) | MX2018007512A (zh) |
PH (1) | PH12018501199A1 (zh) |
PL (1) | PL3393565T3 (zh) |
RU (1) | RU2720573C2 (zh) |
SG (1) | SG11201805204WA (zh) |
UA (1) | UA123586C2 (zh) |
WO (1) | WO2017109678A1 (zh) |
ZA (1) | ZA201803662B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2762860C2 (ru) | 2017-02-28 | 2021-12-23 | Филип Моррис Продактс С.А. | Устройство, генерирующее аэрозоль, содержащее исполнительный элемент для деагломерирования порошка |
WO2019003118A1 (en) * | 2017-06-28 | 2019-01-03 | Philip Morris Products S.A. | CONTAINER WITH PARTICLES FOR USE WITH INHALER |
EP3700611B1 (en) * | 2017-10-25 | 2021-12-01 | Philip Morris Products S.A. | Piercing accessory for inhaler article and system |
WO2019082056A1 (en) * | 2017-10-25 | 2019-05-02 | Philip Morris Products S.A. | INHALER WITH DELIMITATION ELEMENT |
BR112020010021A2 (pt) * | 2017-12-28 | 2020-11-03 | Philip Morris Products S.A. | inalador com túnel de vórtice |
WO2019159123A1 (en) * | 2018-02-19 | 2019-08-22 | Philip Morris Products S.A. | Dry powder inhaler |
JP7458985B2 (ja) | 2018-03-26 | 2024-04-01 | フィリップ・モーリス・プロダクツ・ソシエテ・アノニム | 複合多孔性支持要素を備えた吸入器 |
JP7249354B2 (ja) * | 2018-03-26 | 2023-03-30 | フィリップ・モーリス・プロダクツ・ソシエテ・アノニム | 開口部付きの多孔性支持要素を備えた吸入器 |
US11964099B2 (en) | 2018-03-26 | 2024-04-23 | Philip Morris Products, S.A. | Inhaler with vortex capsule cavity |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4064878A (en) * | 1975-06-13 | 1977-12-27 | Syntex Puerto Rico, Inc. | Inhalation device |
US5673686A (en) * | 1994-02-02 | 1997-10-07 | Plurichemie Anstalt | Medicament inhaler and method |
US6234169B1 (en) * | 1998-08-14 | 2001-05-22 | Arthur Slutsky | Inhaler |
CN1424909A (zh) * | 2000-04-17 | 2003-06-18 | 维克多瑞有限公司 | 吸入器装置中使用的制剂 |
US20040156792A1 (en) * | 2002-12-31 | 2004-08-12 | Nektar Therapeutics | Pharmaceutical formulation with an insoluble active agent |
US20050022812A1 (en) * | 2003-06-13 | 2005-02-03 | Advanced Inhalation Research, Inc. | Low dose pharmaceutical powders for inhalation |
US20050022813A1 (en) * | 2002-12-31 | 2005-02-03 | Nektar Therapeutics (Formerly Inhale Therapeutic Systems, Inc.) | Aerosolization apparatus with rotating capsule |
US20050056280A1 (en) * | 2002-12-31 | 2005-03-17 | Nektar Therapeutics | Receptacle for an aerosolizable pharmaceutical formulation |
US20050081852A1 (en) * | 2002-12-30 | 2005-04-21 | Nektar Therapeutics (Formely Inhale Therapeutic System Inc.) | Package for an aerosolization apparatus and pharmaceutical formulation receptacle |
US20060254583A1 (en) * | 2003-03-20 | 2006-11-16 | Arthur Deboeck | Dry powder inhaler system |
CN101888867A (zh) * | 2007-12-05 | 2010-11-17 | 诺瓦提斯公司 | 用于可雾化的药物制剂的容器 |
US20110220234A1 (en) * | 2008-11-26 | 2011-09-15 | Rouven Haas | Apparatus for taking in powder material and granules and capsule therefor |
WO2015166344A1 (en) * | 2014-04-28 | 2015-11-05 | Philip Morris Products S.A. | Nicotine powder inhaler |
WO2015166350A2 (en) * | 2014-04-28 | 2015-11-05 | Philip Morris Products S.A. | Flavoured nicotine powder inhaler |
WO2015193498A1 (en) * | 2014-06-20 | 2015-12-23 | Philip Morris Products S.A. | Nicotine powder delivery system with airflow management means |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
US4695274A (en) | 1986-01-31 | 1987-09-22 | Fox Richard L | Protected hypodermic needle |
US4790305A (en) | 1986-06-23 | 1988-12-13 | The Johns Hopkins University | Medication delivery system |
US4735217A (en) | 1986-08-21 | 1988-04-05 | The Procter & Gamble Company | Dosing device to provide vaporized medicament to the lungs as a fine aerosol |
GB8804069D0 (en) | 1988-02-22 | 1988-03-23 | Britains Petite Ltd | Dispensers for powdered medication |
IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
NO168921C (no) | 1989-07-31 | 1992-04-22 | Svein Knudsen | Roekfri sigaretterstatning til bruk ved roekavvenning ellertil bruk i roekfrie miljoeer |
US5441060A (en) | 1993-02-08 | 1995-08-15 | Duke University | Dry powder delivery system |
US6102036A (en) | 1994-04-12 | 2000-08-15 | Smoke-Stop | Breath activated inhaler |
GB0009468D0 (en) * | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formulations for use in inhaler devices |
US6681768B2 (en) | 2001-06-22 | 2004-01-27 | Sofotec Gmbh & Co. Kg | Powder formulation disintegrating system and method for dry powder inhalers |
US20040206350A1 (en) | 2002-12-19 | 2004-10-21 | Nektar Therapeutics | Aerosolization apparatus with non-circular aerosolization chamber |
GB2415597A (en) * | 2004-07-01 | 2006-01-04 | Christopher Owen Hackling | Cigarette |
EP1951575B1 (en) | 2005-11-21 | 2009-09-23 | MannKind Corporation | Powder dispensing and sensing apparatus and methods |
GB2461008B (en) | 2006-12-08 | 2011-08-10 | Exchange Supplies Ltd | Nicotine inhalation device |
CA2682432C (en) | 2007-03-30 | 2017-06-06 | Duke University | Device and method for delivery of a medicament |
US8485180B2 (en) * | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
UA97784C2 (ru) | 2009-02-23 | 2012-03-12 | Джапан Тобакко Инк. | Ненагреваемое устройство для всасывания табачного аромата |
US8813759B1 (en) | 2010-11-18 | 2014-08-26 | Richard C. Horian | Nicotine inhaler and method of manufacture |
WO2012078804A1 (en) | 2010-12-07 | 2012-06-14 | Respira Therapeutics, Inc. | Dry powder inhaler |
JP6037315B2 (ja) | 2011-05-27 | 2016-12-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 吸入器及び吸入器用カプセル |
CA2841402C (en) | 2011-07-13 | 2021-10-26 | Pharmaxis Ltd | Improvements relating to delivery devices |
US20140088044A1 (en) | 2012-09-21 | 2014-03-27 | Basil Rigas | Product comprising a nicotine-containing material and an anti-cancer agent |
US9980521B2 (en) * | 2014-06-27 | 2018-05-29 | Philip Morris Products S.A. | Aerosol-generating system with improved piercing member |
RU2716195C2 (ru) * | 2015-04-15 | 2020-03-06 | Филип Моррис Продактс С.А. | Устройство для введения в ингалятор вкусового ароматизирующего вещества |
US20170071248A1 (en) * | 2015-09-16 | 2017-03-16 | Sansa Corporation (Barbados) Inc. | System and Method for Controlling the Harshness of Nicotine-Based Dry Powder Formulations |
-
2016
- 2016-12-19 ES ES16826768T patent/ES2948157T3/es active Active
- 2016-12-19 PL PL16826768.0T patent/PL3393565T3/pl unknown
- 2016-12-19 AU AU2016376033A patent/AU2016376033A1/en not_active Abandoned
- 2016-12-19 RU RU2018126867A patent/RU2720573C2/ru active
- 2016-12-19 UA UAA201803894A patent/UA123586C2/uk unknown
- 2016-12-19 SG SG11201805204WA patent/SG11201805204WA/en unknown
- 2016-12-19 WO PCT/IB2016/057792 patent/WO2017109678A1/en active Application Filing
- 2016-12-19 US US16/064,177 patent/US10960152B2/en active Active
- 2016-12-19 CA CA3008996A patent/CA3008996A1/en not_active Abandoned
- 2016-12-19 EP EP16826768.0A patent/EP3393565B1/en active Active
- 2016-12-19 MX MX2018007512A patent/MX2018007512A/es unknown
- 2016-12-19 CN CN201680071326.0A patent/CN108430551A/zh active Pending
- 2016-12-19 KR KR1020187016263A patent/KR20180096611A/ko active IP Right Grant
- 2016-12-19 JP JP2018530623A patent/JP7242300B2/ja active Active
- 2016-12-19 BR BR112018010830-8A patent/BR112018010830B1/pt active IP Right Grant
-
2018
- 2018-06-01 ZA ZA2018/03662A patent/ZA201803662B/en unknown
- 2018-06-06 PH PH12018501199A patent/PH12018501199A1/en unknown
- 2018-06-10 IL IL259910A patent/IL259910A/en unknown
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4064878A (en) * | 1975-06-13 | 1977-12-27 | Syntex Puerto Rico, Inc. | Inhalation device |
US5673686A (en) * | 1994-02-02 | 1997-10-07 | Plurichemie Anstalt | Medicament inhaler and method |
US6234169B1 (en) * | 1998-08-14 | 2001-05-22 | Arthur Slutsky | Inhaler |
CN1424909A (zh) * | 2000-04-17 | 2003-06-18 | 维克多瑞有限公司 | 吸入器装置中使用的制剂 |
US20050081852A1 (en) * | 2002-12-30 | 2005-04-21 | Nektar Therapeutics (Formely Inhale Therapeutic System Inc.) | Package for an aerosolization apparatus and pharmaceutical formulation receptacle |
US20050022813A1 (en) * | 2002-12-31 | 2005-02-03 | Nektar Therapeutics (Formerly Inhale Therapeutic Systems, Inc.) | Aerosolization apparatus with rotating capsule |
US20050056280A1 (en) * | 2002-12-31 | 2005-03-17 | Nektar Therapeutics | Receptacle for an aerosolizable pharmaceutical formulation |
US20040156792A1 (en) * | 2002-12-31 | 2004-08-12 | Nektar Therapeutics | Pharmaceutical formulation with an insoluble active agent |
US20060254583A1 (en) * | 2003-03-20 | 2006-11-16 | Arthur Deboeck | Dry powder inhaler system |
US20050022812A1 (en) * | 2003-06-13 | 2005-02-03 | Advanced Inhalation Research, Inc. | Low dose pharmaceutical powders for inhalation |
CN101888867A (zh) * | 2007-12-05 | 2010-11-17 | 诺瓦提斯公司 | 用于可雾化的药物制剂的容器 |
US20110220234A1 (en) * | 2008-11-26 | 2011-09-15 | Rouven Haas | Apparatus for taking in powder material and granules and capsule therefor |
WO2015166344A1 (en) * | 2014-04-28 | 2015-11-05 | Philip Morris Products S.A. | Nicotine powder inhaler |
WO2015166350A2 (en) * | 2014-04-28 | 2015-11-05 | Philip Morris Products S.A. | Flavoured nicotine powder inhaler |
WO2015193498A1 (en) * | 2014-06-20 | 2015-12-23 | Philip Morris Products S.A. | Nicotine powder delivery system with airflow management means |
Also Published As
Publication number | Publication date |
---|---|
MX2018007512A (es) | 2018-09-17 |
JP2019508015A (ja) | 2019-03-28 |
PH12018501199A1 (en) | 2019-01-28 |
ZA201803662B (en) | 2019-07-31 |
ES2948157T3 (es) | 2023-09-01 |
BR112018010830A2 (pt) | 2018-11-27 |
IL259910A (en) | 2018-07-31 |
BR112018010830B1 (pt) | 2023-04-11 |
SG11201805204WA (en) | 2018-07-30 |
RU2720573C2 (ru) | 2020-05-12 |
JP7242300B2 (ja) | 2023-03-20 |
RU2018126867A (ru) | 2020-01-24 |
UA123586C2 (uk) | 2021-04-28 |
US10960152B2 (en) | 2021-03-30 |
WO2017109678A1 (en) | 2017-06-29 |
PL3393565T3 (pl) | 2023-09-11 |
EP3393565A1 (en) | 2018-10-31 |
EP3393565B1 (en) | 2023-05-24 |
KR20180096611A (ko) | 2018-08-29 |
AU2016376033A1 (en) | 2018-06-28 |
CA3008996A1 (en) | 2017-06-29 |
US20190001084A1 (en) | 2019-01-03 |
RU2018126867A3 (zh) | 2020-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108430551A (zh) | 尼古丁颗粒封壳 | |
CN108463262B (zh) | 尼古丁粉末递送系统 | |
CN109328083A (zh) | 尼古丁吸入器系统 | |
CN109922852B (zh) | 具有涡旋端塞的吸入器 | |
CN111801026B (zh) | 具有有孔的多孔支撑元件的吸入器 | |
CN111867662B (zh) | 具有涡旋胶囊腔的吸入器 | |
CN111465423B (zh) | 具有涡旋通道的吸入器 | |
CN111818955B (zh) | 具有复合多孔支撑元件的吸入器 | |
EP3630242B1 (en) | Inhaler article with occluded airflow element | |
CN109922851B (zh) | 具有经大小设定的腔的吸入器 | |
CN109219462B (zh) | 尼古丁粒子递送耗材 | |
US11458263B2 (en) | Nicotine powder consumable article |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |